THE
On 27 May 2017, the Court of Review of Bologna revoked the measure of house arrest against Enzo Lucherini, commercial director of the pharmaceutical company Ibsa Italia, residing in Pescara, accepting the appeal by the defence.
The measure had been ordered by the Parma GIP in relation to the Pasimafi investigation, a complex system of corruption and money laundering which involved large pharmaceutical companies and which in recent days had led to the arrest of numerous people including Guido Fanelli - technical drafter of the Law on Pain Therapy and chairman of the national implementation commission of the same law.
The lawyers Fabrizio Manganiello of the La Scala law firm and Edoardo Rossi, Lucherini's defenders, had filed an appeal against the application of the measure, deducing the absence, not only of the precautionary requirements, but also of the serious indications of guilt for the crimes charged to their own assisted.
Last week the house arrests were also revoked for Marcello and Ugo Grondelli from Parma.
IBSA extension
The pharmaceutical company IBSA (Institut Biochimique SA) was founded in 1945 in Lugano by a group of Swiss biologists. For a long time it was a small company of about 60 employees that marketed only a few products on the local market.
In 1985 IBSA was acquired by the current owners and under the guidance of Dr. Arturo Licenziati – still the President of the Company today – undertook an intense development program which, thanks to innovative technologies, led to the optimization of the active ingredients and the creation of pharmaceutical forms with greater therapeutic efficacy and tolerability.
The Group is now present in more than 70 countries around the world with over 1,800 employees, one third of whom work in Italy: a leading economic and scientific reality in the Italian pharmaceutical sector. The Group develops its business in Lodi, the headquarters of IBSA Farmaceutici Italia and of the subsidiary Bouty, in Rome, the new operational and representative office and last but not least in the production center of Morra de Sanctis (AV). The creation of new subsidiaries and joint ventures abroad has also broadened the Company's area of influence. This phase of expansion is still ongoing.
With more than 55 exclusive international patents, its activities cover different therapeutic areas: pain, sports medicine, orthopedics and rheumatology, endocrinology, uro-gynecology, infertility, pulmonology, dermatology and more recently, cardiometabolic.
